KMPHARMACEUTICAL Co.,Ltd.’s Largest Shareholder Increases Stake... “To Enhance Corporate Value and Strengthen Responsible Management”
Chairman Kang Il-mo Increases Stake to 37.64% Through On-Market Purchases
Reflecting Confidence in the Shift to Life Care... Expanding New Business Ventures
[Edaily Reporter YU JIN-HEE ] KMPHARMACEUTICAL Co.,Ltd.(225430)announced on the 22nd that Chairman Kang Il-mo, the company’s largest shareholder, has purchased additional shares of the company, demonstrating his commitment to enhancing corporate value and strengthening responsible management.
(Photo courtesy of KMPHARMACEUTICAL Co.,Ltd.)
According to the company’s disclosure, Chairman Kang recently acquired 1,490 common shares through on-market purchases. With this purchase, the largest shareholder’s stake has increased to 37.64% from the previous level.
The company explained that this share acquisition was based on confidence in its business expansion toward becoming a specialized life care company—a key priority for KMPHARMACEUTICAL Co.,Ltd.—as well as its mid- to long-term growth strategy. In particular, as the company’s ongoing brand renewal, product portfolio enhancement, and strategies to secure new growth engines are gaining momentum, this move is highly significant in terms of stabilizing management control and enhancing credibility.
A KM Pharmaceutical official explained, “The largest shareholder’s increase in shareholding is a decision that demonstrates a commitment to implementing our current business strategies and strong confidence in them,” adding, “This will serve as an opportunity to further strengthen the competitiveness of our existing OEM (Original Equipment Manufacturing) and ODM (Original Design Manufacturing) businesses while establishing a foundation for sustainable growth.”
The spokesperson added, “We will continue to enhance trust in the market through active communication with shareholders and investors, and we will enhance shareholder value through improved performance and the success of new business ventures.”
Meanwhile, KMPHARMACEUTICAL Co.,Ltd. is pursuing a strategic transformation from its current role as a company specializing in OEM and ODM for oral care and lifestyle beauty products to a life care brand company catering to a diverse range of consumers. The company is focusing its efforts on securing new growth momentum by strengthening product competitiveness centered on functionality and ingredients, fostering new brands, and expanding into domestic and international markets.
The biggest bottleneck for AI servers is memory. As the KV cache—where large language models (LLMs) store past computations—accumulates, the required memory capacity increases exponentially. This prob…
Concerns about “tax risks” have been raised in some quarters of the financial investment, pharmaceutical, and biotech markets regarding Genosco, a subsidiary of OSCOTEC Inc.(039200)specializing in new…
As July began (June 29–July 3), the pharmaceutical and biotech industries turned their attention to Celltrion Pharm Inc.’s large-scale investment in production facilities and AriBio’s successful fundr…
